This Week in Urology — May 14, 2026

Welcome to This Week in Urology. This week we're covering 9 notable papers spanning advancements in prostate cancer diagnostics, outcomes in urologic oncology, and the role of technology and standardization in our procedures. Let's dive in.

We begin this week with prostate cancer, looking at a novel diagnostic test and commentaries on managing advanced disease.

The Study Appearing in *The Journal of Urology*, a prospective multicenter study validates a new semen-based RNA biomarker for prostate cancer detection [5]. Investigators collected semen samples from men prior to prostate biopsy, extracted RNA, and used a machine-learning model to detect cancer. The study enrolled 301 men, with 279 samples ultimately used for model development and validation. The median age was 62 and median PSA was 5.7.

Results In the independent validation cohort, the semen RNA classifier performed impressively. It achieved an Area Under the Curve of 0.90, with a sensitivity of 92% and a specificity of 69%. Critically for clinical decision making, the test had a negative predictive value of 96% for ruling out high-risk cancers, defined as ISUP Grade Group 3 or higher. The authors suggest this test could potentially eliminate 60 to 70 percent of unnecessary biopsies.

Discussion This noninvasive test, which can use samples collected at home, represents a significant potential improvement in our diagnostic pathway. Its ability to confidently rule out high-grade disease could help us better select patients for biopsy and reduce associated morbidity.

Also in the prostate cancer space, two commentaries in *European Urology* highlight ongoing discussions in advanced disease. One is a letter regarding the latest ESMO Clinical Practice Guidelines for advanced and metastatic prostate cancer, reflecting the continuous evolution of our standards of care [1]. Another piece asks whether PSMA-PET Total Tumor Volume is ready for prime time as a response metric [4]. Together, these papers underscore that as our tools for staging and treatment become more sophisticated, the debate on how to best implement and interpret them remains active.

Next, we turn to a major theme this week: outcomes and complications in urologic oncology, with three papers providing crucial data for patient counseling and clinical decision-making.

The Study The largest of these is an international multicenter analysis from the CAMUS Collaborative, published in *European Urology Focus* [3]. This is a massive observational study looking at perioperative complications in over 130,000 major urologic cancer surgeries from 180 centers in 33 countries. The procedures included radical cystectomy, radical and partial nephrectomy, radical prostatectomy, radical nephroureterectomy, and RPLND.

Results The findings provide powerful, real-world benchmarks. Radical cystectomy had the highest morbidity, with 40% of patients experiencing a grade I or II complication within 30 days, and 16% having a high-grade (III to V) complication. The 90-day mortality rate for RC was 2.3%. In contrast, radical prostatectomy had markedly lower complication rates, with a 90-day mortality of less than 0.05%. However, adding an extended pelvic lymph node dissection to RP increased the risk of high-grade complications to 10%. For kidney surgery, 90-day mortality was generally low after partial nephrectomy but reached 1.7% with open radical nephrectomy. Radical nephroureterectomy and RPLND had moderate rates of major complications, up to 14%, but low mortality.

Discussion This study provides the largest standardized global dataset on perioperative morbidity to date, offering invaluable evidence for benchmarking, quality improvement, and, most importantly, for counseling our patients about the real-world risks of these major operations.

Focusing on a specific high-risk population, the European Association of Urology's Renal Cell Carcinoma Guidelines Panel published updated recommendations for lymph node-positive RCC in *European Urology* [7]. The key takeaway is that patients with bulky or multiple nodal metastases often behave like those with metastatic disease. For these patients, the panel suggests they may benefit more from upfront systemic therapy rather than from surgery alone, marking a shift in the treatment paradigm for this challenging group.

Finally, a systematic review and meta-analysis in *BJU International* addresses a crucial long-term survivorship question: the risk of secondary leukemia after treatment for testicular germ cell tumors [8]. The analysis included six studies covering over 57,000 patients with a mean follow-up of nearly 13 years. The results showed that chemotherapy was associated with a significant increase in the relative risk of developing leukemia, with a standardized incidence ratio of 5.77, meaning the risk was increased nearly six-fold compared to the general population. In contrast, radiation therapy showed no statistically significant association. The authors note that while the relative risk from chemotherapy is high, the absolute risk remains small. This is a critical distinction and a vital piece of information for counseling young men undergoing treatment for this highly curable cancer.

Our final section this week examines technology, technique, and the push for standardization across urology.

In the *Journal of Endourology*, a new paper details the development of performance metrics for flexible cystoscopy [6]. This is one of the most common procedures we perform, yet there is significant variability and a lack of standardization. Through a modified Delphi process with 14 international experts, the group established a consensus framework. The final metrics include six distinct phases of the procedure, 24 steps, 25 potential errors, and 16 critical errors. This represents the first international, structured effort to define what optimal performance looks like for flexible cystoscopy. This framework will be foundational for improving training, assessment, and quality assurance moving forward.

Next, a scoping review in the *World Journal of Urology* provides an update on the present and future of ureteral stent technology [2]. The review, conducted by the EAU Endourology section, summarizes advancements in materials, anti-reflux designs, biodegradable stents, novel removal mechanisms, and drug-eluting coatings. The authors reviewed over 1400 studies and synthesized data from 62. The conclusion is clear: despite substantial and diverse innovations, a universal “ideal” stent does not yet exist. The future of stent development is likely to focus on patient-specific customization. For now, this review serves as a comprehensive catalog of the current technological landscape.

Lastly, a narrative review in *Neurourology and Urodynamics* explores the application of artificial intelligence in interpreting urodynamic studies [9]. The interpretation of multichannel pressure-flow data is notoriously complex and subject to interobserver variability. This review assessed 12 studies where AI, including machine learning and deep learning, was used to analyze urodynamic tracings. The AI models were applied to tasks like detecting detrusor overactivity, classifying bladder outlet obstruction, and even real-time event detection. Performance was generally high, with many models reporting accuracies or AUCs between 80 and 95 percent. However, the authors caution that the field is still in its infancy. Most studies are retrospective, single-center, and lack external validation. While AI shows strong potential to bring objectivity and efficiency to urodynamics, it remains an emerging research area that requires more robust validation before clinical adoption.

If you only have time for one paper this week, make it the study on semen RNA-based biomarkers for prostate cancer in *The Journal of Urology* [5]. This prospective validation of a noninvasive test that can reliably rule out high-grade disease could fundamentally change our diagnostic algorithms and spare a significant number of men from unnecessary biopsies.

Here are the key takeaways from this week in Urology:

First, a new semen-based RNA test shows high accuracy for detecting prostate cancer and, more importantly, has a 96% negative predictive value for ruling out high-grade disease, potentially avoiding up to 70% of prostate biopsies.

Second, the largest-ever real-world analysis of urologic oncology complications confirms that radical cystectomy is our most morbid procedure, with a 2.3% 90-day mortality, providing crucial benchmarks for patient counseling.

Third, for patients with testicular cancer, chemotherapy is associated with a nearly six-fold increased relative risk of secondary leukemia, whereas radiation is not. This is a key counseling point, though the absolute risk remains small.

Fourth, for patients with node-positive renal cell carcinoma who have bulky or multiple nodes, updated EAU panel recommendations suggest considering upfront systemic therapy rather than surgery alone.

And finally, for the first time, we have an internationally validated, standardized set of performance metrics for flexible cystoscopy, which will provide the foundation for future education and quality assurance initiatives.

That's your roundup for This Week in Urology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.